EGFR and small cell lung carcinoma: Another patient with SCLC transformation (patient 218, Fig 6A) harboured an EGFR L858R‐activating mutation at diagnosis, and again demonstrated a good clinical and radiological response, with progression‐free survival of 14 months on first‐line EGFR‐TKI (Fig 6B).